Author: Nicole Dragonetti
FDA Approves Firdapse® (Amifampridine) For The Treatment Of Lambert-Eaton Myasthenic Syndrome (LEMS)

CORAL GABLES, Fla., Nov. 29, 2018 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Firdapse® (amifampridine) 10 mg tablets for the treatment […]

SOL Global Investments Reports Record Financial Results For Six-Months Ended September 30, 2018
| PRNewswire

TORONTO, Nov. 29, 2018 /PRNewswire/ – SOL Global Investments Corp. (“SOL” or the “Company”) (CSE: SOL) (OTCQB: SOLCF) (Frankfurt:9SB) today reported record financial results for the six-months ended on September 30, 2018.

SpinalCyte Earns FDA Clearance For Fibroblast Cell Therapy: 5 Things To Know
| Becker's Spine Review

SpinalCyte received FDA Investigational New Drug clearance for CybroCell, its fibroblast-based therapy to treat degenerative disc disease.